SP-101 gene therapy shows promise for cystic fibrosis treatment

Scientists from Spirovant Sciences describe SP-101, a novel adeno-associated virus (AAV) gene therapy for the treatment of cystic fibrosis (CF) in the peer-reviewed journal Human Gene Therapy. They also showed that after single dose inhaled delivery of SP-101, SP-101 vector genomes were detected throughout the respiratory tract of CF ferrets. 

Cystic fibrosis is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Katherine Excoffon, and coauthors from Spirovant Sciences, describe SP-101, an AAV gene therapy vector that has been optimized for efficient human airway cell transduction, and that contains a functional and regulated shortened human CFTR minigene (hCFTRΔR).

The investigators showed that hCFTRΔR mRNA expression was highest in ferrets that also received single does inhaled doxorubicin, an AAV transduction augmenter.

"SP-101 mediated hCFTRΔR mRNA expression was clearly apparent in all SP-101 dose groups 2-weeks and 13-weeks post-dose," stated the investigators.

In in vitro studies, "functional correction of CF human airway epithelia increased with increasing multiplicity of infection and doxorubicin concentration and correlated with increasing cell-associated vector genomes and hCFTRΔR mRNA expression."

A number of efforts to use AAV for CF gene therapy have fallen short on efficiency and duration of gene transfer. The vector described by Excoffon and colleagues combines a number of improvements in an attempt to overcome these obstacles and fulfill the unmet needs of CF patients for whom effective CFTR modulators are not available."

Editor in Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School

Source:
Journal reference:

Excoffon, K. JDA., et al. (2024). SP-101, a novel adeno-associated virus gene therapy for the treatment of cystic fibrosis, mediates functional correction of primary human airway epithelia from donors with cystic fibrosis. Human Gene Therapy. doi.org/10.1089/hum.2024.063.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The role of CRISPR-Cas9 in combating mosquito-borne diseases